While medical device manufacturers and trade groups fully support a recently proposed Medicare Coverage Of Innovative Technology (MCIT) regulation, commercial insurers are more skeptical, industry attorneys said on 11 November at King & Spalding’s 13th Annual Medical Device Summit.
The MCIT program – once it goes into effect – will supply a glide path for Medicare coverage of any US Food and Drug Administration breakthrough device for a four-year...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?